News
Latest news from CHV and our portfolio companies
Featured News
Milestone marks the commercial use of the first and only liquid embolic approved for hypervascular tumor embolization supported by a prospective, randomized, controlled clinical trial BEDFORD, Mass., January 28th, 2026 – Instylla,…
Insights & Impacts: The latest from CHV
Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health
PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital
Data to be presented on February 3rd during a Spotlight Session at AF Symposium 2023
Novel Foam-Based Design Demonstrates Successful LAAO Seal with No Device-Related Thrombus Conformal Medical, Inc., a
Rejoni announced today that it has closed a $25 million Series B financing. The round
– Clinical and economic benefits of the PreTRM® test and treat strategy illustrated amongst diverse
AtaCor Medical, Inc. has announced completion of its second human clinical study of the Extravascular
Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health
Seasoned Medical Device Executive, James Reinstein, Appointed as Chief Executive Officer Conformal Medical, Inc., a
– Grant Supports Continued Clinical Development of the Company’s PTM-101 Product and its Potential for